- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Antares Announces 2020 Revenue Guidance Range of up to US$155 Million
Antares announced its 2020 net revenue guidance of US$135 to US$155 million, which includes potential revenue scenarios for AMAG’s Makena.
Antares Pharma (NASDAQ:ATRS) today announced its 2020 full-year net revenue guidance of US$135 to US$155 million, which includes a range of potential revenue scenarios for AMAG’s Makena.
As quoted in the press release:
In addition, the Company also announced that full-year 2019 revenue is expected to be at the upper end or exceed our revenue guidance of $115 to $120 million.
Robert F. Apple, President and Chief Executive Officer of the Company, stated, “We are extremely pleased with the significant commercial progress we made last year driven primarily by increased prescriptions for XYOSTED along with strong and growing demand for Teva’s generic epipen. As a result, we believe 2019 full-year reported revenue will be at the upper end or exceed our guidance range of $115 to $120 million.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.